Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS; PATH study group. van Schaik IN, et al. Among authors: lawo jp. Trials. 2016 Jul 25;17(1):345. doi: 10.1186/s13063-016-1466-2. Trials. 2016. PMID: 27455854 Free PMC article. Clinical Trial.
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Léger JM; PRIMA trial investigators. Merkies ISJ, et al. Among authors: lawo jp. J Peripher Nerv Syst. 2017 Jun;22(2):149-152. doi: 10.1111/jns.12204. J Peripher Nerv Syst. 2017. PMID: 28594116 Free PMC article. Clinical Trial. No abstract available.
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Among authors: lawo jp. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Free article. Clinical Trial.
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group. Mielke O, et al. Among authors: lawo jp. J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1. J Peripher Nerv Syst. 2019. PMID: 30672067 Free PMC article.
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group. Merkies ISJ, et al. Among authors: lawo jp. J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15. J Peripher Nerv Syst. 2019. PMID: 30672091 Free PMC article. Clinical Trial.
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Among authors: lawo jp. Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31355323 Free PMC article. Clinical Trial.
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
Tortorici MA, Yuraszeck T, Cornblath D, Bril V, Hartung HP, Sobue G, Lewis RA, Merkies ISJ, Lawo JP, Praus M, Durn BL, Mielke O, Ma X, Jauslin P, Pfister M, van Schaik IN; PATH study group. Tortorici MA, et al. Among authors: lawo jp. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):839-850. doi: 10.1002/psp4.12647. Epub 2021 Aug 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34085779 Free PMC article.
36 results